

# Primary Prophylaxis of Venous Thromboembolism in Surgical Patients

*Eric K. Peden, MD*

*Peter H. Lin, MD*

The following article is the first in a series addressing the important topic of improving the quality and safety of surgical care. To promote awareness, *Hospital Physician* is publishing a series of clinical review articles focused on recent evidence-based recommendations for lowering the incidence of perioperative complications and general approaches to improving surgical quality of care. Some surgical complications cannot be avoided. However, system-wide efforts to promote adherence to evidence-based practice recommendations and to bolster patient safeguards can significantly reduce the rate of surgical complications. Successful efforts to improve the quality of surgical care are increasingly being reported in the medical literature.

Four articles in this series will highlight clinical areas targeted by the Surgical Care Improvement Project (SCIP), a national quality partnership of organizations concerned with reducing surgical complications. Among the many SCIP partners are the Centers for Disease Control and Prevention, the Centers for Medicare & Medicaid Services, the Joint Commission, and the Veterans Health Administration. Currently, SCIP is focused on 4 preventable surgical complications that can result in significant morbidity and increased cost of health care: venous thromboembolism, pneumonia, surgical site infection, and myocardial infarction. The following clinical review article is first of the SCIP-focused papers. The fifth article in this series will address the quality in surgical care and best practices in measuring outcomes.

**M**ore than 23 million patients undergo operations each year in the United States.<sup>1</sup> Prevention of perioperative complications remains one of the most important aspects of clinical care in patients undergoing surgical treatment. Venous thromboembolism (VTE) is a major threat to surgical patients during the perioperative period. VTE, which occurs with a relatively high frequency among surgical patients, refers to thrombotic occlusion within the venous system and includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Because DVT typically occurs in the lower extremity, this condition is further defined as *distal DVT* (occlusion confined to the deep calf veins) or *proximal DVT* (thrombosis at or above the popliteal vein). Without appropriate prophylaxis against VTE, a distal or proximal DVT may result in PE, which can be fatal.

In the absence of prophylaxis, DVT occurs after approximately 20% of all major surgical procedures and PE occurs after 1% to 2%.<sup>2</sup> The prevalence of VTE is even higher in orthopedic patients: more than 50% of major orthopedic procedures are complicated by DVT and up to 30% by PE when VTE prophylaxis is not instituted.<sup>3,4</sup> Without prophylaxis, the frequency

of fatal postoperative PE ranges from 0.1% to 0.4% in patients undergoing elective general surgery and from 1% to 5% in patients undergoing elective hip or knee surgery, emergency hip surgery, and surgery for major trauma or spinal cord injury.<sup>5-7</sup>

The emphasis on prevention of VTE, as opposed to treating only symptomatic episodes, has a multifactorial rationale. Although most cases of postsurgical VTE remain asymptomatic,<sup>4,8</sup> VTE is associated with significant morbidity, mortality, and costs of care.<sup>9,10</sup> The 1-year mortality rate of DVT is estimated to be 16% to 30%, with most deaths occurring within the first month.<sup>4,11</sup> VTE prophylaxis does not afford complete protection; however, it has been shown to be cost-effective as well as clinically efficacious, with DVT rates

---

*Dr. Itani is a professor of surgery, Boston University; an associate chief of surgery, Boston Medical Center and Brigham & Women's Hospital, and chief of surgery, Boston Veteran's Administration Health Care System, Boston, MA. Dr. Peden is chief, Division of Vascular Surgery, The Methodist Hospital Physicians Organization, Houston, TX. Dr. Lin is an associate professor of surgery and chief, Division of Vascular Surgery & Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and the Michael E. DeBakey Veteran's Administration Medical Center, Houston, TX.*

### TAKE HOME POINTS

- Venous thromboembolism (VTE) refers to thrombotic occlusion within the venous system and includes deep vein thrombosis (DVT) and pulmonary embolism (PE). A distal or proximal DVT may result in PE, which can be fatal.
- Risk factors leading to the development of VTE in surgical patients during the perioperative period include age, type of surgery, duration of postoperative immobilization, and underlying medical comorbidities, hypercoagulable disorders, and malignancy.
- Without prophylaxis, DVT occurs after approximately 20% of all major surgical procedures and PE occurs after 1% to 2%.
- The most effective modality for preventing VTE in most surgical patients is pharmacologic prophylaxis, which includes anticoagulant drugs, antiplatelet drugs, and direct thrombin inhibitors. Efficacy of pharmacologic prophylaxis may be improved when combined with mechanical prophylaxis.
- Current guidelines classify patients as low, moderate, high, or highest risk. Low-risk patients do not require specific prophylaxis other than early mobilization. For all other patients, recommendations for pharmacologic prophylaxis with or without nonpharmacologic prophylaxis vary by surgery type and patient risk profile.

reduced by 70% or more.<sup>11–14</sup> In addition, prophylactic anticoagulation therapy is effective in preventing DVT and PE-related mortality.<sup>2,15,16</sup> However, studies continue to show common underutilization of VTE prophylaxis. Observational studies have documented that nearly half of hospitalized patients who developed DVT did not receive adequate VTE prophylaxis.<sup>3,4</sup> Additionally, autopsy studies have demonstrated that for the majority of cases of confirmed PE, this diagnosis was not considered prior to death.<sup>13</sup> Barriers to appropriate VTE prophylaxis include the perception that VTE is uncommon, a lack of acceptance of the importance of VTE prophylaxis, and concerns about hemorrhagic complications in surgical patients.

This article reviews the epidemiology of VTE, the methods for achieving VTE prophylaxis, and the approach to instituting VTE prophylaxis in surgical patients.

### RISK FACTORS, PATHOGENESIS, AND CLINICAL COURSE

Patients undergoing surgical procedures are at an

**Table 1.** Common Risk Factors for Venous Thromboembolism

Permission to electronically reproduce this table not granted by copyright holder.

Adapted with permission from Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3Suppl):340S.

increased risk for developing VTE, due in part to the physiologic stress as well as potential postoperative immobility.<sup>17</sup> VTE often results from a combination of risk factors, including inherited, acquired, environmental, and idiopathic conditions.<sup>18</sup> Relevant risk factors leading to the development of VTE vary widely and include factors such as age, type of surgery, duration of postoperative immobilization, underlying medical comorbidities, underlying hypercoagulable disorders, and underlying malignancy (**Table 1**).<sup>14,19</sup> The 2004 American College of Chest Physicians (ACCP) recommendations<sup>19</sup> for VTE prophylaxis divide surgical patients into 4 risk categories (**Table 2**).<sup>14</sup>

The pathogenesis of venous thrombosis involves Virchow's triad: damage to the vessel wall, venous stasis, and hypercoagulability. VTE typically originates in the venous sinuses of the calf muscles but can occur in the proximal veins due to trauma or surgery.<sup>7</sup> Twenty-five percent of postoperative DVT cases involve proximal deep veins, which are much more likely to cause symptoms and result in PE.<sup>20</sup> Of distal DVT cases, 10% to 20% are thought to propagate to proximal DVT.<sup>3,4,11</sup> It has been estimated that half or more of DVTs

**Table 2.** Levels of Thromboembolism Risk in Surgical Patients Without VTE Prophylaxis

---

Permission to electronically reproduce this table  
not granted by copyright holder.

---

Adapted with permission from Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. *Chest* 2001;119(1 Suppl):134S.

GCS = graduated compression stockings; INR = international normalized ratio; IPC = intermittent pneumatic compression devices; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin; VKA = vitamin K antagonist; VTE = venous thromboembolism.

begin intraoperatively.<sup>221</sup> Several of these clots resolve spontaneously, and the addition of postoperative prophylactic agents facilitates this resolution. For patients at greatest risk, longer duration of prophylaxis correlates with further reductions in the incidence of DVT, which adds evidence to the concept that many cases of DVT occur later in the postoperative course.

Associated signs and symptoms of DVT result from venous outflow obstruction and from inflammation of the vessel wall and perivascular tissue.<sup>18</sup> The potential complications of DVT include worsening acute venous symptoms with development of phlegmasia and possible limb loss; development of PE and subsequent death; recurrent thromboembolic events; and the development of chronic venous insufficiency due to post-thrombotic syndrome. In phlegmasia cerulea dolens, the thrombosis extends to collateral veins, which can lead to massive fluid sequestration. Clinical symptoms include significant leg swelling, bluish discoloration, and pain. In phlegmasia alba dolens, the thrombosis involves major deep venous channels of the extremity, therefore sparing collateral veins. The venous drainage is decreased but still present, and it is frequently associated with lymphangitis. Clinical symptoms include a large, swollen, and painful limb made pale by severe edema. Limb loss can be a devastating sequela if phlegmasia is left untreated. Calf vein thrombi often undergo spontaneous thrombolysis but rarely result in symptomatic PE;<sup>22</sup> however, approximately 25% of untreated

calf thrombi extend into the proximal veins, usually within a week after presentation.<sup>23</sup> The risk of PE (either symptomatic or asymptomatic) with proximal DVT is approximately 50%, and most fatal emboli usually originate from proximal thrombi.<sup>24,25</sup> The development of postthrombotic syndrome is a function of the extent of thrombosis, its subsequent effect on venous valvular competence, and long-term residual obstruction. The consequences of postthrombotic syndrome and chronic venous insufficiency are quite severe, with persistent edema, pain, and recurring skin problems (eg, ulcerations). These problems lead to decreased quality of life and considerable economic burden.

### PHARMACOLOGIC PROPHYLAXIS

Pharmacologic prophylaxis is the most effective modality for prevention of VTE in surgical patients. A brief review of the mechanisms of action is provided as a basis for understanding the different drugs and their unique properties. Commonly used antithrombotic dosing regimens for VTE prophylaxis are shown in **Table 3**.<sup>26</sup>

#### Anticoagulants

**Heparin.** Heparin is a highly sulfated glycosaminoglycan that binds to antithrombin, which markedly accelerates inactivation of thrombin, activated factor X (factor Xa), and activated factor IX (factor IXa).<sup>27</sup> Additional antithrombotic effects include release of a tissue factor pathway inhibitor and some platelet binding.<sup>27,28</sup>

At therapeutic concentrations, heparin has a half-life of about 60 minutes. Its clearance is dose dependent. Heparin has decreased bioavailability when administered subcutaneously in low doses but has approximately 90% bioavailability when administered in high therapeutic doses.<sup>26</sup>

Low-dose unfractionated heparin (UFH) has been in clinical use for many years. In general surgery patients, UFH has been shown to reduce VTE by 70%.<sup>29</sup> A downside to UFH is the unpredictable treatment response to full anticoagulation. Heparin binds to a number of plasma proteins, a phenomenon that reduces its anticoagulant effect by limiting the accessibility of heparin to antithrombin. The concentration of heparin-binding proteins also increases during illness, which contributes to the variability in anticoagulant response.<sup>30</sup> Because of this variability, response to heparin should be monitored with the activated partial thromboplastin time (aPTT). The dose should be adjusted as necessary to achieve a therapeutic range, which for many aPTT reagents corresponds to an aPTT ratio of 1.5 to 2.5.<sup>26</sup> It is also this binding to plasma proteins, specifically platelet factor 4, that can lead to heparin-induced thrombocytopenia (HIT).<sup>31,32</sup>

Standard prophylactic dosing for patients undergoing general surgical procedures is typically 5000 U of low-dose UFH subcutaneously 1 to 2 hours preoperatively, which is continued 2 or 3 times daily postoperatively until the patient is ambulatory or is discharged home.<sup>19</sup> For orthopedic patients, low-dose UFH is typically given at a dose of 5000 U subcutaneously 2 hours before surgery and 5000 U every 8 or 12 hours after surgery.<sup>7</sup> The more frequent dosing schedule seems to be somewhat more effective without any increased complications noted. Risk for major bleeding from UFH in prophylactic doses has not been found to exceed that of placebo; however, risk for wound hematomas has been shown to be 2% higher with UFH than with placebo.<sup>30</sup> Higher rates of osteopenia and osteoporosis have also been reported in patients treated with long-term UFH.<sup>33</sup>

**Low-molecular-weight heparin.** Low-molecular-weight heparin (LMWH) is derived from standard commercial-grade heparin by chemical depolymerization to yield fragments approximately one third the size of heparin.<sup>27</sup> Depolymerization changes the anticoagulant profile, bioavailability, and pharmacokinetics of heparin, resulting in a lower incidence of HIT and of osteopenia.<sup>26,28</sup> LMWH works by binding to and markedly enhancing the activity of antithrombin. In contrast to UFH, there is much more specificity against factor Xa with very little effect against thrombin. Decreased

**Table 3.** Commonly Used Antithrombotic Dosing Regimens for VTE Prophylaxis

Medication	Adult Dosing Regimens
UFH	Initial dose: 80 U/kg IV bolus Maintenance: 18 U/kg/hr continuous IV infusion
Enoxaparin	30 mg SC every 12 hr or 40 mg/day for an average of 7–14 days
Dalteparin	2500–5000 U/day SC for an average of 7–14 days; current recommended dose in patients undergoing abdominal surgery is 2500 U/day SC
Fondaparinux sodium*	2.5 mg/day SC; initial dose recommended to be given 6–8 hr following surgery once hemostasis is established; administration < 6 hr after surgery associated with increased risk of major bleeding
Warfarin	5–10 mg PO 4 times daily; adjust dose according to desired INR; therapy is initiated without a loading dose at a dose range of 5–10 mg/day for 70-kg adult; monitor PT/INR daily during initiation of therapy to measure anticoagulation effect; after initial 5–10 days and stabilization of warfarin dose, measure PT/INR 2–3 times each week for 2–4 wk, then monthly thereafter

Adapted with permission of John Wiley & Sons, Inc. Desai UR. New antithrombin-based anticoagulants. *Med Res Rev* 2004;24:151–81.

INR = international normalized ratio; IV = intravenously; PO = by mouth; PT = prothrombin time; SC = subcutaneously; UFH = unfractionated heparin; VTE = venous thromboembolism.

\*Approved for use in hip fracture surgery, knee replacement surgery, and hip replacement surgery. Fondaparinux is the only US Food and Drug Administration–approved anticoagulant drug for hip fracture surgery. It is also approved for extended prophylactic dosing (21 days) following hip fracture surgery.

binding to plasma proteins translates into increased bioavailability and longer half-life, enabling weight-based daily dosing without laboratory monitoring. Another benefit of LMWH is that long-term dosing is associated with lower rates of osteoporosis than with UFH.<sup>34</sup>

In contrast to UFH, LMWH is cleared almost entirely by the kidneys. Renal clearance of LMWH is therefore less predictable in patients with severe renal insufficiency, defined in most studies as a creatinine clearance of less than 30 mL/min. In these patients, laboratory monitoring of anti-Xa levels is prudent. LMWH dosing is also less predictable in morbidly obese patients (body mass index > 50) due to metabolic variables and may require monitoring during full anticoagulation. Decreased binding to plasma proteins, specifically platelet factor 4, results in a decreased incidence of HIT. Even so, patients with HIT should not receive LMWH, because cross-reactivity with UFH does occur.<sup>31,32</sup>

The LMWHs used in VTE prophylaxis are enoxaparin, dalteparin, danaparoid, and nadroparin. Dosing

regimens for enoxaparin and dalteparin are provided in Table 3.

**Fondaparinux** is a new parenteral synthetic anticoagulant composed of the 5 saccharide units that comprise the active site of heparin that binds antithrombin.<sup>35,36</sup> The fondaparinux antithrombin complex inhibits factor Xa but has no direct activity against thrombin. Fondaparinux is rapidly absorbed and is 100% bioavailable when administered subcutaneously. Fondaparinux has better bioavailability and a longer half-life than LMWH. It is not metabolized, is renally excreted, and has a dose-independent elimination half-life of 15 hours, which makes it suitable for once-daily administration. Fondaparinux has been approved for thrombosis prophylaxis in hip and knee joint replacement surgery and is being evaluated for VTE prophylaxis in the high-risk abdominal patient. One potential advantage of fondaparinux over both LMWH and UFH is that the risk for HIT is substantially lower.<sup>37</sup> The dosing regimen for fondaparinux is provided in Table 3.

**Warfarin.** Warfarin is an oral anticoagulant that competitively inhibits production of vitamin K–dependent clotting factors in the liver by producing hemostatically defective, vitamin K–dependent coagulant proteins (prothrombin; factors VII, IX, and X; and the anticoagulant proteins C and S).<sup>38</sup> Warfarin is completely absorbed after oral administration, with peak concentration generally achieved within the first 4 hours. Its anticoagulation effect generally occurs within 24 hours after drug administration. However, peak anticoagulant effect may be delayed 72 to 96 hours. The duration of action of a single dose of this anticoagulant ranges from 2 to 5 days. The elimination of warfarin is completely by metabolism, with its metabolites principally excreted into the urine.<sup>34</sup>

The dose of warfarin must be monitored closely because the anticoagulant response varies widely among individuals. Laboratory monitoring is performed by measuring the prothrombin time (PT), a test responsive to depression of 3 of the 4 vitamin K–dependent clotting factors (prothrombin and factors VII and X). Commercial PT reagents vary markedly in their responsiveness to warfarin-induced reduction in clotting factors, a problem that has been overcome by the introduction of the international normalized ratio (INR).<sup>39</sup>

The starting dose of warfarin is typically 10 mg, with an average maintenance dose of approximately 5 mg. Elderly patients require lower doses. Evidence indicates that it might be safer to use a starting dose of 5 mg of warfarin because, compared with 10 mg, the 5-mg starting dose does not result in a delay in achieving a thera-

peutic INR and is associated with a lower incidence of supratherapeutic INR values during the first 5 days of treatment.<sup>39</sup> In some patients, unexpected fluctuations in dose response occur, which may reflect changes in diet, inaccuracy in PT testing, undisclosed drug use, poor compliance, or surreptitious self-medication. Patients receiving warfarin are also sensitive to fluctuating levels of dietary vitamin K, which is obtained predominantly from leafy green vegetables. The effect of warfarin can be potentiated in sick patients with poor vitamin K intake, if they are treated with antibiotics and intravenous feeding without vitamin K supplementation, and in states of fat malabsorption.

Moderate-dose warfarin (INR, 2.0–3.0) is effective for preventing postoperative VTE in patients in all risk categories.<sup>39</sup> Warfarin therapy can be started preoperatively, at the time of surgery, or in the early postoperative period. Although the anticoagulant effect is not achieved until the third or fourth postoperative day, warfarin treatment started at the time of surgery or in the early postoperative period is effective in highest-risk patients, including patients with hip fractures and those who undergo joint replacement. However, warfarin is not generally used for perioperative VTE prophylaxis in surgical patients as it typically requires several days to reach its therapeutic level. In addition, prophylaxis with warfarin is less convenient than prophylaxis with low-dose UFH or LMWHs because warfarin requires careful laboratory monitoring.

### **Antiplatelet Therapy**

Aspirin is a nonsteroidal anti-inflammatory drug commonly used in treating fever, pain, and bodily inflammation. Aspirin exerts its pharmacologic effect by suppressing the production of prostaglandins and thromboxanes via irreversible inhibition of the cyclooxygenase enzymes. Prostaglandins are hormones that have diverse effects in the body, including but not limited to transmission of pain information to the brain, modulation of the hypothalamic thermostat, and inflammation. Thromboxanes are responsible for the aggregation of platelets that leads to formation of an intraluminal thrombus.<sup>40</sup> Because aspirin can inhibit platelet aggregation, it has been considered for VTE prophylaxis. However, aspirin therapy is considered ineffective for VTE prophylaxis in surgical patients. Original support for its usage came from collections of very small studies with small numbers of patients, which are quite old. More modern studies involving aspirin have shown that it is far inferior to LMWHs and UFH.<sup>19,41,42</sup> Additionally, aspirin has been linked to increased risk of bleeding, which further discourages its use.<sup>40</sup> Given the available

literature, antiplatelet therapy is not the standard of care for the prevention of VTE in surgical patients.

### **Direct Thrombin Inhibitors**

Ximelagatran is a direct thrombin inhibitor that is currently being evaluated for primary prevention and acute and long-term treatment of VTE.<sup>43,44</sup> Ximelagatran has no known food or drug interactions and is administered orally. Once absorbed from the gastrointestinal tract, ximelagatran is converted to melagatran, a partial mimetic of fibrinopeptide A, which blocks the active site of thrombin.<sup>43</sup> Ximelagatran is primarily eliminated by the kidneys and has a half-life of about 3 hours, mandating twice-daily administration. It has been studied for VTE prophylaxis in orthopedic patients and appears to be equally efficacious as LMWH.<sup>44</sup> However, it has not yet received US Food and Drug Administration approval.

### **Complications of Antithrombotic Therapy**

Bleeding remains the most common complication of antithrombotic therapy.<sup>45,46</sup> The risk of bleeding caused by antithrombotic agents is influenced by the dose and by patient-related factors, the most important being recent surgery or trauma. Other patient characteristics that increase the risk of bleeding are older age, recent stroke, generalized hemostatic defect, a history of gastrointestinal hemorrhage, and serious comorbid conditions.<sup>45,46</sup> Bleeding complications with UFH and LMWHs are similar.<sup>47</sup> With UFH, the incidence of bleeding is influenced by dosage and by means of administration, bleeding events being more common with intermittent intravenous therapy than with continuous intravenous therapy.<sup>48</sup> The incidence of bleeding complications with fondaparinux is higher than with LMWHs.<sup>35,36</sup> Bleeding associated with warfarin is influenced by the intensity of anticoagulant therapy.<sup>49</sup> The risk for bleeding is reduced by approximately one third if the targeted INR range is lowered from between 3.0 and 4.5 to between 2.0 and 3.0. Both heparin-induced bleeding and warfarin-induced bleeding are increased by concomitant use of aspirin, which impairs platelet function and produces gastric erosions. When the INR is less than 3.0, warfarin-associated bleeding frequently has an obvious underlying cause or is from an occult gastrointestinal or renal lesion.

Nonhemorrhagic side effects of heparin include the following: (1) urticaria at sites of subcutaneous injection; (2) thrombocytopenia, which occurs in 2% to 4% of patients treated with high-dose heparin and is complicated by arterial or venous thrombosis in about 0.2% of treated patients; (3) osteoporosis and osteopenia, which occur with prolonged high-dose heparin use; and (4) alopecia, adrenal insufficiency, and skin necro-

sis (all of which are rare).<sup>47</sup> The incidence of thrombocytopenia is lower with LMWHs than with heparin. Similarly, there is evidence that the risk of osteopenia is lower with LMWH than with heparin.<sup>47</sup>

The most important nonhemorrhagic side effect of warfarin is skin necrosis, an uncommon complication usually observed on the third to eighth day of therapy.<sup>50</sup> Skin necrosis is caused by extensive thrombosis of the venules and capillaries within the subcutaneous fat. An association has been reported between warfarin-induced skin necrosis and protein C deficiency and, less commonly, protein S deficiency (this complication can also occur in patients without these deficiencies). Because warfarin inhibits vitamin-K dependent coagulation factors, including protein C and S, patients who require antithrombotic therapy should receive heparin or LMWH first and then be transitioned to warfarin oral anticoagulation. This approach reduces the likelihood of depleting protein C or S levels in these patients.

### **NONPHARMACOLOGIC PROPHYLAXIS**

#### **Mechanical Prophylaxis**

Mechanical prophylaxis is an attractive option for VTE prophylaxis because there is no associated increased risk of bleeding. It is therefore most useful in patients who are deemed to be at high risk for bleeding complications from pharmacologic prophylaxis. Mechanical means of VTE prophylaxis include graduated compression stockings (GCS), intermittent pneumatic compression (IPC) devices, and venous foot pumps (Table 2). The latter 2 devices rely on a common mechanical principle of providing an intermittent compressive effect on the lower venous circulation. Their mechanism of action is reduction in stasis and perhaps a local increase in fibrinolytic activity. Both GCS and IPC devices increase venous blood flow and decrease venous stasis. IPC devices also stimulate endogenous fibrinolytic activity by causing gentle trauma to the vascular endothelial cells of the lower leg and by altering rheological characteristics and perfusion pressure.<sup>51,52</sup> Because the history of venous foot pumps in VTE prophylaxis is relatively recent, the role of these devices as a sole means of VTE prophylaxis in surgical patients remains to be validated. IPC is the method of choice for preventing VTE in patients undergoing neurosurgery, is effective in patients undergoing major knee surgery, and is as effective as low-dose UFH in patients undergoing abdominal surgery.<sup>53</sup> GCS are relatively inexpensive and should be considered in all high-risk surgical patients, even if other forms of prophylaxis are used.<sup>54</sup> GCS should be used with caution in patients with significant arterial insufficiency as there have been reports of worsening limb ischemia and tissue loss.<sup>55</sup>

In direct comparison studies, mechanical prophylaxis has been found to be better than no prophylaxis but less effective than pharmacologic means.<sup>56</sup> When mechanical prophylaxis is combined with pharmacologic prophylaxis, there is enhanced protection over pharmacologic treatment alone. This additive effect is predictable, based on the approach of both relieving venous stasis and correcting or preventing hypercoagulability.<sup>21,56–59</sup>

Perhaps the biggest problem with mechanical prophylaxis, however, is compliance. Stockings must be adequately sized and properly fitted. Compression devices only work while in place and commonly are found at the foot of the bed or on the floor in the patient's room in clinical practice. Patient compliance with mechanical prophylaxis is generally well maintained when the treatment is conducted within a clinical study protocol. However, it appears that outside clinical trials where compliance is carefully maintained, day-to-day use proves less reliable and is less efficacious.

### **Inferior Vena Cava Filters**

Placement of prophylactic inferior vena cava (IVC) filters is effective for prevention of PE. Naturally, there is no impact on incidence of DVT, as it is not a prophylactic measure against DVT. Accepted indications for IVC filters are patients with PE despite anticoagulation, patients with symptomatic VTE and a contraindication to anticoagulation or a complication of anticoagulation, and patients requiring pulmonary embolectomy for PE.<sup>60</sup> Relative indications have included patients with a large DVT ("free floating" iliofemoral DVT), problems with compliance with anticoagulation therapy, and patients with VTE and limited cardiopulmonary reserve.

Although the incidence of complications is small, IVC filters pose some risk of caval thrombosis and, by some reports, increase the chance of a future DVT. Additionally, many patients who are at greatest risk for developing PE are only at risk for a relatively short period. These factors led to the recent development of retrievable IVC filters. IVC filters can be safely removed as long as 1 year after implantation, which has encouraged the placement of these filters in a large number of patients. Prophylactic retrievable IVC filters have been most commonly placed in patients felt to be at high risk for VTE, in whom anticoagulation is not advisable or is contraindicated (eg, trauma patients with spine or brain injuries, patients undergoing bariatric surgery). Review of the literature, however, shows no strong evidence to support those practices, as PE is still an uncommon occurrence even in highest-risk groups.<sup>60</sup> The indications for placement of retrievable IVC filters, therefore, remain in evolution and currently must be

based on individual or regional practice patterns until large trials are available to provide evidence to support specific recommendations. The ACCP guidelines do not currently recommend the use of IVC filters.<sup>19</sup>

### **APPROACH TO PRIMARY PROPHYLAXIS OF VTE**

The most effective approach to reducing VTE-related morbidity and mortality is to institute primary prophylaxis in patients at risk for VTE. Based on well-defined clinical criteria, the 2004 ACCP recommendations<sup>19</sup> for VTE prophylaxis classify surgical patients as low, moderate, high, or highest risk for VTE (Table 2).<sup>14</sup> The choice of prophylaxis should be tailored to the patient's risk. Clearly, early mobilization is the least costly, and, for many low-risk patients, a highly effective method of VTE prophylaxis. For patients who are medically and physically able to get out of bed and are at low risk for VTE, this is sufficient. Immobilized or higher-risk patients require a more active means of VTE prophylaxis, which is accomplished either by modulating activation of blood coagulation or by preventing venous stasis by using the following proven approaches: low-dose subcutaneous UFH, IPC of the legs, warfarin, adjusted doses of subcutaneous UFH, GCS, LMWH, or fondaparinux.<sup>6,61,62</sup>

### **Indications for Prophylaxis**

**General surgery.** Clearly, the type and length of surgery are directly related to the incidence of VTE. As always, the approach to prophylaxis should be tailored to the patient's risk for developing VTE (Table 2). In the low-risk group of patients (patients undergoing relatively minor procedures [eg, laparoscopic cholecystectomy]), no specific prophylaxis other than early mobilization is needed based on the extremely low incidence of VTE in this patient population. Higher-risk patients require active prophylaxis. In general, UFH and LMWH are more efficacious than mechanical prophylaxis alone, and patients treated with LMWH are less likely to develop symptomatic DVT. However, the overall incidence of symptomatic DVT, PE, complications, and death are similar between the 2 agents.<sup>19</sup> Prophylaxis recommendations for moderate-risk patients are UFH twice daily or LMWH and for high-risk patients are UFH 3 times daily or LMWH. Highest-risk patients should receive UFH 3 times daily or LMWH combined with GCS and/or IPC. In select general surgery patients at highest risk (eg, those undergoing cancer surgery), consideration should be given to prolonged prophylaxis (up to 1 mo) after hospital discharge. If anticoagulants are contraindicated because of an unusually high risk of bleeding, GCS, IPC of the legs, or both should be used.<sup>19</sup>

**Trauma surgery.** Trauma patients, especially those

with spinal cord injury, severe brain injury, pelvic fracture, or burns and those with lengthy periods of immobilization, are at very high risk for VTE, with a reported rate of 60% or greater.<sup>63</sup> Pharmacologic VTE prophylaxis in this group has been studied, and LMWH has been found to be superior to UFH, with 60% less proximal DVT.<sup>64,65</sup> Therefore, it is recommended that these patients receive LMWH. If the patients cannot be treated with LMWH because of bleeding concerns, mechanical prophylaxis should be initiated and then LMWH started once the risk of bleeding is reduced. For patients with prolonged immobility, including any period of inpatient rehabilitation, the ACCP recommends prophylaxis until discharge.<sup>19</sup> Burn patients as well are at risk for VTE, and it is recommended that those with 1 additional risk factor for VTE begin prophylaxis with UFH or LMWH as soon as possible.<sup>19</sup>

**Orthopedic surgery.** In general, LMWH, fondaparinux, and warfarin provide effective VTE prophylaxis in patients undergoing hip surgery, while LMWH, warfarin, fondaparinux, and IPC provide effective VTE prophylaxis in patients undergoing major knee surgery.<sup>16,19</sup> The ACCP guidelines recommend that prophylaxis for all patients undergoing orthopedic operations should be at least 10 days.<sup>19</sup> Extended prophylaxis with LMWH or warfarin for 28 to 35 days after hospital discharge should be considered after major orthopedic surgery. Extended prophylaxis is also strongly recommended for high-risk patients (eg, patients with previous VTE or active cancer).<sup>16,19</sup>

Low-dose UFH is less effective than warfarin, adjusted-dose heparin, or LMWHs in patients undergoing major orthopedic surgical procedures.<sup>7</sup> For patients undergoing hip or major knee surgery, LMWH is more effective than warfarin but is also associated with more frequent bleeding, both of which may be caused by a more rapid onset of anticoagulation with postoperatively initiated LMWH than with warfarin.<sup>66,67</sup> It is uncertain whether the superior efficacy of LMWH over warfarin in preventing venographically detectable venous thrombosis is mirrored by fewer symptomatic episodes of VTE with LMWH.<sup>66,67</sup> Results in joint surgery patients suggest that fondaparinux is somewhat more effective than LMWH but is also associated with a higher incidence of bleeding complications.<sup>35,36</sup> The relative efficacy and safety of aspirin versus LMWH, fondaparinux, or warfarin in patients who have a hip fracture or have undergone hip or knee arthroplasty is uncertain. However, studies have shown that aspirin is much less effective than LMWH or warfarin at preventing venographically detectable venous thrombosis. Therefore, aspirin is not recommended as

the sole agent for postoperative prophylaxis.<sup>16,19,68</sup> Ultimately, selection of a prophylactic agent must be based on the patient's specific risk profile for complications.

ACCP recommendations for VTE prophylaxis for specific orthopedic procedures are summarized below.

- **Elective hip or knee arthroplasty.** Patients undergoing elective total hip replacement should receive 1 of the following VTE prophylaxis strategies: (1) LMWH (at a usual high-risk dose, started 12 hr before surgery or 12–24 hr after surgery; or 4–6 hr after surgery at half the usual high-risk dose and then increasing to the usual high-risk dose the following day); (2) fondaparinux (2.5 mg started 6–8 hr after surgery); or (3) adjusted-dose warfarin started preoperatively or the evening after surgery (INR target, 2.5; INR range, 2.0–3.0).<sup>19</sup> Patients undergoing elective knee arthroplasty should receive VTE prophylaxis with LMWH (using a high-risk dose), fondaparinux (2.5 mg/day), or adjusted-dose warfarin (target INR, 2.5; INR range, 2.0–3.0).<sup>19</sup>
- **Knee arthroplasty.** Low-risk patients do not require any specific prophylaxis intervention other than early mobilization. In patients at higher risk due to preexisting VTE risk factors or following a prolonged/complicated procedure, LMWH is indicated.<sup>19</sup>
- **Hip fracture surgery.** Patients undergoing hip fracture surgery should receive routine fondaparinux, LMWH at the usual high-risk dose, low-dose UFH, or adjusted-dose warfarin (target INR, 2.5; INR range, 2.0–3.0). Patients whose surgery may be delayed should receive prophylaxis with low-dose UFH or LMWH during the time between hospital admission and surgery. In the event that anticoagulant prophylaxis is contraindicated due to high risk of bleeding during hip surgery, these patients should receive mechanical prophylaxis including both GCS and IPC.<sup>19</sup>

**Vascular surgery.** Interestingly, vascular surgery patients appear to be at low risk for VTE. Randomized trials have demonstrated no benefit of prophylaxis over placebo, although the studies were small.<sup>69,70</sup> The ACCP guidelines<sup>19</sup> do not recommend any specific VTE prophylaxis unless additional risk factors are present, in which case, UFH or LMWH is recommended. Preoperative dosing is rarely needed as most of these patients receive UFH intraoperatively, but postoperative treatment should be considered for those who remain at bed rest for a prolonged period.

**Gynecologic and urologic surgery.** Based on the ACCP recommendations, no specific VTE prophylaxis is needed other than early mobilization for patients



undergoing brief (< 30 min) gynecologic surgery or transurethral or low-risk urologic procedures.<sup>19</sup> Patients undergoing laparoscopic gynecologic surgical procedures who have additional VTE risk factors should undergo at least 1 of the VTE prophylactic strategies, such as low-dose UFH, LMWH, IPC, or GCS. All patients undergoing major gynecologic operations should receive VTE prophylaxis until they are discharged from the hospital. Elderly women (≥ 60 yr) undergoing gynecologic cancer surgery or who have had a previous episode of VTE should receive VTE prophylaxis for 2 to 4 weeks following hospital discharge.

Patients undergoing major or open urologic procedures should receive VTE prophylaxis, such as low-dose UFH 2 or 3 times daily. Alternative strategies may include LMWH, IPC, and/or GCS. Urologic patients with multiple VTE risk factors (Table 1) should be treated with combinations of GCS and/or IPC with low-dose UFH or LMWH.<sup>19</sup>

**Neurosurgery.** Neurosurgery patients should routinely receive VTE prophylaxis. GCS reduce venous stasis and prevent postoperative VTE in surgical patients with neurologic disorders, including paralysis of the lower limbs.<sup>71,72</sup> IPC with or without GCS is effective prophylaxis for VTE in patients undergoing intracranial surgery and does not increase the risk of bleeding.<sup>16,34</sup> Alternatively, these patients can be treated with low-dose UFH or postoperative LMWH. High-risk neurosurgical patients with multiple VTE risk factors should receive a combination of mechanical prophylaxis (GCS and/or IPC) as well as pharmacologic prophylaxis, including low-dose UFH or LMWH.<sup>19</sup>

## CONCLUSION

Probably the most important factor in preventing VTE in surgical patients is recognizing the need to institute primary VTE prophylaxis. Choice of prophylactic modality is best based on risk group assessment. Pharmacologic prophylaxis continues to be the most effective method. Future developments will likely include the approval of oral agents with greatly improved ease of administration. The role for removable IVC filters will hopefully become better defined with further study. **HP**

*Corresponding author: Peter H. Lin, MD, HVAMC 112, 2002 Holcombe Boulevard, Houston, TX 77401; plin@bcm.edu.*

## REFERENCES

1. Liu JH, Etzioni DA, O'Connell JB, et al. The increasing workload of general surgery. *Arch Surg* 2004;139:423–8.
2. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. *Ann Surg* 1988;208:227–40.
3. Geerts W, Ray JG, Colwell CW, et al. Prevention of venous thromboembolism [letter]. *Chest* 2005;128:3775–6.
4. Geerts WH. Prevention of venous thromboembolism in high-risk patients. *Hematology Am Soc Hematol Educ Program* 2006:462–6.
5. Hirsh J. Current anticoagulant therapy—unmet clinical needs. *Thromb Res* 2003;109 Suppl 1:S1–8.
6. Muntz JE. Deep vein thrombosis and pulmonary embolism in the perioperative patient. *Am J Manag Care* 2000;6 (20 Suppl):S1045–52.
7. Stamatakis JD, Kakkar VV, Sagar S, et al. Femoral vein thrombosis and total hip replacement. *Br Med J* 1977;2: 223–5.
8. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. *Chest* 2003;124(6 Suppl):386S–392S.
9. Bick RL, Haas S. Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients. *Hematol Oncol Clin North Am* 2003;17:217–58.
10. Bick RL, Haas SK. International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997. *Med Clin North Am* 1998;82:613–33.
11. Haas S. The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. *Haemostasis* 1996;26 Suppl 2: 39–48.
12. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. *Clin Orthop Relat Res* 1995;(321):19–27.
13. Ageno W, Turpie AG. Deep venous thrombosis in the medically ill. *Curr Hematol Rep* 2002;1:73–8.
14. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. *Chest* 2001;119(1 Suppl):132S–175S.
15. Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous thromboembolism. *Chest* 1998;114:531S–560S.
16. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. *JAMA* 1986;256: 744–9.
17. Reasbeck PG, Guerrini S, Harper J, et al. Incidence of deep vein thrombosis after major abdominal surgery in Brisbane. *Br J Surg* 1988;75:440–3.
18. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. *N Engl J Med* 2004;351:268–77.
19. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126 (3 Suppl):338S–400S.
20. Arcelus JI, Caprini JA, Monreal M, et al. The management

- and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. *J Vasc Surg* 2003; 38:916–22.
21. Kelsey LJ, Fry DM, VanderKolk WE. Thrombosis risk in the trauma patient. Prevention and treatment. *Hematol Oncol Clin North Am* 2000;14:417–30.
  22. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? *Ann Intern Med* 1981;94 (4 Pt 1):439–44.
  23. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. *Lancet* 1985;2:515–8.
  24. Moser KM, Fedullo PF, Litlejohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis [published erratum appears in *JAMA* 1994;271:1908]. *JAMA* 1994;271:223–5.
  25. Galle C, Papazyan JP, Miron MJ, et al. Prediction of pulmonary embolism extent by clinical findings, D-dimer level and deep vein thrombosis shown by ultrasound. *Thromb Haemost* 2001;86:1156–60.
  26. Desai UR. New antithrombin-based anticoagulants. *Med Res Rev* 2004;24:151–81.
  27. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. *Transfus Med Rev* 2007;21:37–48.
  28. Mosesson MW. Fibrinogen and fibrin structure and functions. *J Thromb Haemost* 2005;3:1894–904.
  29. Wiles N, Hunt BJ. Anticoagulation via anti-Factor Xa inhibition. *Lupus* 2006;15:167–71.
  30. Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. *Trends Cardiovasc Med* 2002;12:331–8.
  31. Warkentin TE. HIT: lessons learned. *Pathophysiol Haemost Thromb* 2006;35:50–7.
  32. Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. *Pathophysiol Haemost Thromb* 2006;35:37–45.
  33. Merli G. Anticoagulants in the treatment of deep vein thrombosis. *Am J Med* 2005;118 Suppl 8A:13S–20S.
  34. Nutescu EA. Emerging options in the treatment of venous thromboembolism. *Am J Health Syst Pharm* 2004;61 (23 Suppl 7):S12–7.
  35. Tran AH, Lee G. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. *Ann Pharmacother* 2003;37:1632–43.
  36. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first selective factor Xa inhibitor. *Curr Opin Hematol* 2003;10:327–32.
  37. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. *Semin Thromb Hemost* 2006;32:803–9.
  38. Cosmi B, Palareti G. Oral anticoagulant therapy in venous thromboembolism. *Semin Vasc Med* 2003;3:303–14.
  39. Riley RS, Rowe D, Fisher LM. Clinical utilization of the international normalized ratio (INR). *J Clin Lab Anal* 2000;14: 101–14.
  40. Arab D, Lewis B, Cho L, et al. Antiplatelet therapy in anticoagulated patients requiring coronary intervention. *J Invasive Cardiol* 2005;17:549–54.
  41. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. *Pharmacotherapy* 2001;21:218–34.
  42. Dunn CJ, Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease [published erratum appears in *Drugs* 2000;60:719]. *Drugs* 2000;60: 203–37.
  43. Motsch J, Walther A, Bock M, Bottiger BW. Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism. *Curr Opin Anaesthesiol* 2006;19: 52–8.
  44. Schulman S. The role of ximelagatran in the treatment of venous thromboembolism. *Pathophysiol Haemost Thromb* 2005;34 Suppl 1:18–24.
  45. Gumulec J, Kessler P, Penka M, et al. [Hemorrhagic complications during warfarin treatment.] [Article in Czech.] *Vnitř Lek* 2006;52 Suppl 1:79–91.
  46. Brigden ML. When bleeding complicates oral anticoagulant therapy. How to anticipate, investigate, and treat. *Postgrad Med* 1995;98:153–4, 159–62, 164–5, passim.
  47. Samama MM, Bara L, Gouin-Thibault I. New data on the pharmacology of heparin and low molecular weight heparins. *Drugs* 1996;52 Suppl 7:8–15.
  48. Pineo GF, Hull RD. Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly. *Clin Appl Thromb Hemost* 2005;11:15–23.
  49. Makris M. Management of excessive anticoagulation or bleeding. *Semin Vasc Med* 2003;3:279–84.
  50. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation [published errata appear in *Am Fam Physician* 1999;60:1333, 2002;65:172, and 2006;73:974]. *Am Fam Physician* 1999;59:635–46.
  51. Comerota AJ, Chouhan V, Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. *Ann Surg* 1997;226: 306–14.
  52. Kessler CM, Hirsch DR, Jacobs H, et al. Intermittent pneumatic compression in chronic venous insufficiency favorably affects fibrinolytic potential and platelet activation. *Blood Coagul Fibrinolysis* 1996;7:437–46.
  53. Urbankova J, Quiroz R, Kucher N, Goldhaber SZ. Intermittent pneumatic compression and deep vein thrombosis prevention. A meta-analysis in postoperative patients. *Thromb Haemost* 2005;94:1181–5.
  54. Goldhaber SZ, Hirsch DR, MacDougall RC, et al. Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). *Am J Cardiol* 1995;76:993–6.
  55. Comerota AJ. Modern day treatment of acute deep venous thrombosis. *Aust N Z J Surg* 1995;65:773–9.
  56. Cornwell EE 3rd, Chang D, Velmahos G, et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. *Am Surg* 2002;

*(continued on page 49)*

(from page 27)

- 68:470-3.
57. Winemiller MH, Stolp-Smith KA, Silverstein MD, Theraudeau TM. Prevention of venous thromboembolism in patients with spinal cord injury: effects of sequential pneumatic compression and heparin. *J Spinal Cord Med* 1999;22:182-91.
  58. Spain DA, Bergamini TM, Hoffmann JF, et al. Comparison of sequential compression devices and foot pumps for prophylaxis of deep venous thrombosis in high-risk trauma patients. *Am Surg* 1998;64:522-6.
  59. Knudson MM, Lewis FR, Clinton A, et al. Prevention of venous thromboembolism in trauma patients. *J Trauma* 1994;37:480-7.
  60. el Sayed HF, Kougias P, Zhou W, Lin PH. Utility of retrievable vena cava filters and mechanical thrombectomy in the endovascular management of acute deep venous thrombosis. *Vascular* 2006;14:305-12.
  61. O'Shaughnessy DF. Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs. *Int J Clin Pract* 2004;58:277-84.
  62. Gallus AS, Coghlan DW. Heparin pentasaccharide. *Curr Opin Hematol* 2002;9:422-9.
  63. Frezza EE, Chiriva-Internati M. Venous thromboembolism in morbid obesity and trauma. A review of literature. *Minerva Chir* 2005;60:391-9.
  64. Davidson BL. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients. *Haemostasis* 2000;30 Suppl 2:63,77-81.
  65. Pini M, Tagliaferri A, Manotti C, et al. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. *Int Angiol* 1989;8:134-9.
  66. Liu LT, Ma BT. Prophylaxis against venous thromboembolism in orthopedic surgery. *Chin J Traumatol* 2006;9:249-56.
  67. Agnelli G, Sonaglia F. Prevention of venous thromboembolism in high risk patients. *Haematologica* 1997;82:496-502.
  68. Colwell CW Jr. Thromboprophylaxis in orthopedic surgery. *Annenberg Center for Health Sciences and Quadrant Medical Education. Am J Orthop* 2006; Suppl:1-9.
  69. Swedenborg J, Nydahl S, Egberg N. Low molecular mass heparin instead of unfractionated heparin during infringuinal bypass surgery. *Eur J Vasc Endovasc Surg* 1996;11:59-64.
  70. Melissari E, Stringer MD, Kakkar VV. The effect of a bolus injection of unfractionated or low molecular weight heparin during aortobifemoral bypass grafting. *Eur J Vasc Surg* 1989;3:121-6.
  71. Green D. Prevention of thromboembolism after spinal cord injury. *Semin Thromb Hemost* 1991;17:347-50.
  72. Smith SF, Simpson JM, Sekhon LH. Prophylaxis for deep venous thrombosis in neurosurgical oncology: review of 2779 admissions over a 9-year period. *Neurosurg Focus* 2004;17:E4.

Copyright 2007 by Turner White Communications Inc., Wayne, PA. All rights reserved.